Ross Gary, Shoaib Taimur, Soutar David S, Camilleri Ivan G, Gray Henry W, Bessent Rodney G, Robertson Andrew G, MacDonald D Gordon
Plastic Surgery Unit, Canniesburn Hospital, Switchback Road, Bearsden, Glasgow G61 1QL, Scotland.
Arch Otolaryngol Head Neck Surg. 2002 Nov;128(11):1287-91. doi: 10.1001/archotol.128.11.1287.
To investigate the possible role of sentinel node biopsy (SNB) alone to upstage the clinically N0 neck in patients with oral and oropharyngeal squamous cell carcinoma.
Prospective clinical study.
Head and neck referral center.
Patients with primary untreated oral and/or oropharyngeal squamous cell carcinoma accessible to injection and with clinically N0 necks were enrolled in the study.
An SNB was performed after radiocolloid and blue dye injection. Preoperative lymphoscintigraphy and the perioperative use of a gamma probe identified radioactive sentinel nodes and visualization of blue-stained lymphatics identified blue sentinel nodes. If the sentinel node was found negative, there was no further treatment to the neck. If the sentinel node tested positive, a therapeutic neck dissection was performed. All patients underwent regular follow-up at the outpatient clinic to identify possible recurrence.
Upstaging of the clinically N0 neck by SNB and development of subsequent disease in SNB-negative necks.
An SNB was performed on 57 clinically N0 necks in 48 patients. Sentinel nodes were harvested in 43 (90%) of 48 patients. Fifteen (35%) of 43 patients were upstaged by SNB and 28 (65%) of 43 were staged SNB negative. There was a mean follow-up of 18 months. One patient developed subsequent disease after having been staged negative with SNB. The overall sensitivity of the procedure using the full pathologic protocol was 94% (15/16).
Sentinel node biopsy can be used to upstage the N0 neck in patients with early subclinical nodal disease. However, before it becomes the standard of care in head and neck squamous cell carcinoma, longer follow-up observational trials are needed.
探讨前哨淋巴结活检(SNB)单独用于提高口腔和口咽鳞状细胞癌患者临床N0颈部分期的可能作用。
前瞻性临床研究。
头颈转诊中心。
纳入原发性未经治疗、可注射且临床颈部为N0的口腔和/或口咽鳞状细胞癌患者。
注射放射性胶体和蓝色染料后进行前哨淋巴结活检。术前淋巴闪烁显像和术中使用γ探测仪确定放射性前哨淋巴结,蓝色淋巴管显影确定蓝色前哨淋巴结。如果前哨淋巴结为阴性,则不对颈部进行进一步治疗。如果前哨淋巴结检测为阳性,则进行治疗性颈清扫术。所有患者在门诊定期随访以确定可能的复发情况。
前哨淋巴结活检对临床N0颈部的分期提升情况以及前哨淋巴结阴性颈部后续疾病的发生情况。
对48例患者的57个临床N0颈部进行了前哨淋巴结活检。48例患者中有43例(90%)获取了前哨淋巴结。43例患者中有15例(35%)经前哨淋巴结活检分期提升,43例中有28例(65%)前哨淋巴结活检分期为阴性。平均随访18个月。1例患者在前哨淋巴结活检分期为阴性后出现了后续疾病。采用完整病理方案该手术的总体敏感性为94%(15/16)。
前哨淋巴结活检可用于提高早期亚临床淋巴结疾病患者的N0颈部分期。然而,在其成为头颈鳞状细胞癌的标准治疗方法之前,需要进行更长时间的随访观察试验。